Panagora Asset Management Inc Glycomimetics Inc Transaction History

Panagora Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$2.16 - $3.18 $140,531 - $206,893	-65,061 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$2.89 - $4.22 $118,784 - $173,450	-41,102 Reduced 38.72%	65,061 $196,000
Q4 2020 Feb 10, 2021	SELL	$2.69 - $4.24 $195,552 - $308,231	-72,696 Reduced 40.64%	106,163 $399,000
Q3 2020 Nov 13, 2020	SELL	$3.07 - $5.0 $589 - $960	-192 Reduced 0.11%	178,859 $549,000
Q2 2020 Aug 12, 2020	SELL	$2.06 - $3.76 $35,499 - $64,796	-17,233 Reduced 8.78%	179,051 $673,000
Q1 2020 May 14, 2020	BUY	$1.83 - $5.41 $142,765 - $422,055	78,014 Added 65.96%	196,284 $447,000
Q4 2019 Feb 12, 2020	BUY	$4.03 - $6.5 $476,628 - $768,755	118,270 New	118,270 $626,000

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.